PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
News|Articles|December 2, 2013
SGS Poitiers Lab Receives GMP Certification
Author(s)Pharmaceutical Technology Editors
SGS Life Science Services announced that its bioanalytical laboratory in Poitiers, France has received GMP certification, following approval from ANSM.
Advertisement
SGS Life Science Services announced that its bioanalytical laboratory in Poitiers, France has received GMP certification, following approval from the Agence Nationale de Sécurité du Médicaments et des Produits de Santé (ANSM), the French agency charged with ensuring the quality of drug products. With this GMP certification, the laboratory can provide tests required for final batch release, the company reports in a press statement.
The GMP services will be performed in dedicated suites and controlled access areas of 200 square meters. The facility has been operating under GLP since 1994. With the Life Science Services laboratory in Clichy, France, the company provides services covering GMP activities for small and large molecules.
By bringing GMP to the Poitiers site, the company can offer cell-based assays for testing of biologics, including biosimilars. The company plans to bring bioanalytical capability to the West Coast of North America with a new facility in Carson, Cailf.
Source:
Advertisement
Related to this article
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.
Lori Dingledine, QC Director Microbiological Control and GTIC Operations at Genentech, provided input on the regulations surrounding raw material manufacturing and use for ATMPs in a presentation at the 2026 PDA/FDA Joint Regulatory Conference.
FDA opens applications for its Expedited IND Pilot, pairing sponsors with qualified research institutions to test rolling CMC review ahead of first-in-human trials.
2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
Karthik Iyer, Eli Lilly, details an AI system linking GMP findings, audits, and deviations for cited, inspection-ready regulatory intelligence.
At the PDA/FDA Joint Regulatory Conference 2026, Helen Motamen, MS
global head, Sanofi Quality Audit, Inspection, Intelligence & Advocacy, at Sanofi, provided advice for creating a strong internal audit program.
At PDA/FDA Joint Regulatory Conference 2026, PCI Pharma's Bassler details how a QMS overhaul turned an FDA 483 into stronger quality culture.
Advertisement
Advertisement